128 related articles for article (PubMed ID: 10450984)
1. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists.
Ahn HS; Arik L; Boykow G; Burnett DA; Caplen MA; Czarniecki M; Domalski MS; Foster C; Manna M; Stamford AW; Wu Y
Bioorg Med Chem Lett; 1999 Jul; 9(14):2073-8. PubMed ID: 10450984
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist.
Ahn HS; Foster C; Boykow G; Stamford A; Manna M; Graziano M
Biochem Pharmacol; 2000 Nov; 60(10):1425-34. PubMed ID: 11020444
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1).
Nantermet PG; Barrow JC; Lundell GF; Pellicore JM; Rittle KE; Young M; Freidinger RM; Connolly TM; Condra C; Karczewski J; Bednar RA; Gaul SL; Gould RJ; Prendergast K; Selnick HG
Bioorg Med Chem Lett; 2002 Feb; 12(3):319-23. PubMed ID: 11814787
[TBL] [Abstract][Full Text] [Related]
4. Thrombin receptor (PAR-1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif.
Hoekstra WJ; Hulshizer BL; McComsey DF; Andrade-Gordon P; Kauffman JA; Addo MF; Oksenberg D; Scarborough RM; Maryanoff BE
Bioorg Med Chem Lett; 1998 Jul; 8(13):1649-54. PubMed ID: 9873407
[TBL] [Abstract][Full Text] [Related]
5. Non-peptidic small-molecule antagonists of the human platelet thrombin receptor PAR-1.
Selnick HG; Barrow JC; Nantermet PG; Connolly TM
Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):47-59. PubMed ID: 15317290
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
7. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
[TBL] [Abstract][Full Text] [Related]
8. Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time.
Nadal-Wollbold F; Bocquet A; Bourbon T; Létienne R; Le Grand B
Eur J Pharmacol; 2010 Oct; 644(1-3):188-94. PubMed ID: 20655904
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of platelet aggregation inhibitory activity of some 3-phenyl-pyrroloquinazolinones.
Ferlin MG; Borgo C; Deana R
Eur J Med Chem; 2012 Feb; 48():275-83. PubMed ID: 22236469
[TBL] [Abstract][Full Text] [Related]
10. Development of CoMFA, advance CoMFA and CoMSIA models in pyrroloquinazolines as thrombin receptor antagonist.
Dixit A; Kashaw SK; Gaur S; Saxena AK
Bioorg Med Chem; 2004 Jul; 12(13):3591-8. PubMed ID: 15186843
[TBL] [Abstract][Full Text] [Related]
11. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist.
Kato Y; Kita Y; Nishio M; Hirasawa Y; Ito K; Yamanaka T; Motoyama Y; Seki J
Eur J Pharmacol; 1999 Nov; 384(2-3):197-202. PubMed ID: 10611442
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold.
Liu S; Yuan D; Li S; Xie R; Kong Y; Zhu X
Eur J Med Chem; 2021 Dec; 225():113764. PubMed ID: 34391031
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-platelet evaluation of 2-benzoylaminobenzoate analogs.
Hsieh PW; Chiang SZ; Wu CC; Lo YC; Shih YT; Wu YC
Bioorg Med Chem; 2008 May; 16(10):5803-14. PubMed ID: 18407506
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1).
Maryanoff BE; Zhang HC; Andrade-Gordon P; Derian CK
Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):13-36. PubMed ID: 15317288
[TBL] [Abstract][Full Text] [Related]
16. A novel molecular design of thrombin receptor antagonist.
Fujita T; Nakajima M; Inoue Y; Nose T; Shimohigashi Y
Bioorg Med Chem Lett; 1999 May; 9(10):1351-6. PubMed ID: 10360734
[TBL] [Abstract][Full Text] [Related]
17. New platelet aggregation inhibitors based on pyridazinone moiety.
Costas T; Costas-Lago MC; Vila N; Besada P; Cano E; Terán C
Eur J Med Chem; 2015 Apr; 94():113-22. PubMed ID: 25757094
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of proteinase-activated receptor agonists on human platelets.
Chung AW; Jurasz P; Hollenberg MD; Radomski MW
Br J Pharmacol; 2002 Mar; 135(5):1123-32. PubMed ID: 11877318
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of para-fluorophenylalanine amide derivatives as thrombin receptor antagonists.
Fujita T; Nose T; Nakajima M; Inoue Y; Costa T; Shimohigashi Y
J Biochem; 1999 Jul; 126(1):174-9. PubMed ID: 10393336
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet thromboxane receptor function by a thrombin receptor-targeted pepducin.
Stampfuss JJ; Schrör K; Weber AA
Nat Med; 2003 Dec; 9(12):1447; author reply 1447-8. PubMed ID: 14647510
[No Abstract] [Full Text] [Related]
[Next] [New Search]
